PRESS RELEASE:

On September 8, 2011, two advisory panels to the U.S. Food and Drug Administration* (“FDA”) convened to discuss the safety of bisphosphonates such as Fosamax, which are used in the treatment of osteoporosis.  Although the participants declined to make a recommendation as to whether the use of Fosamax and similar medications should be limited, according to The Wall Street Journal, the panel is “particularly concerned about reports of unusual thigh fractures seen in some women who had been treated with Fosamax and similar drugs for several years, and said doctors need to evaluate patients currently on the drugs to see if therapy should be stopped.”  In addition, the panel voted 17 to 6 in favor of recommending that changes should be made to the drugs’ labeling to warn consumers about potential risks associated with long-term use, such as Fosamax femur fractures. In addition, many panelists intimated that the updated Fosamax warning label should specify how often users need to visit their doctors and be re-evaluated as to whether they need to continue using the medications.  Although the lawyers at Bernstein Liebhard LLP were hopeful that the advisory panels would provide conclusive recommendations limiting the use of Fosamax, the Firm is pleased that the advisors recognized that the current Fosamax warning label should be strengthened and cautionary language added.

FDA Warning Regarding Fosamax Femur Fractures

In October 2010, the FDA issued a Fosamax femur fracture warning** that Fosamax and other bisphosphonates put patients at risk for atypical thigh bone (femur) fractures.  Since that time, Bernstein Liebhard LLP has provided a wealth of consumer information concerning the risks associated with Fosamax use on its website, www.consumerinjurylawyers.com.  If you or a loved one took Fosamax and sustained a femur fracture, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.

* fda.gov/AdvisoryCommittees/Calendar/ucm262477.htm

**fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm

For more information about filing a Fosamax femur fracture lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at info@consumerinjurylawyers.com.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products.  The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country for the past nine consecutive years.  Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2011 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Published September 14, 2011 by